Archive for the ‘Other topics’ Category
Stephan Moll, MD writes... The annual American Society of Hematology (ASH) meeting took place in Dec 2014 in San Francisco. A summary of the clinically relevant thrombosis and anticoagulation presentation and abstracts is presented here (Top 10 ASH Highlights).
Disclosure: I have been a consultant to Portola, Daiichi, Janssen, and Boehringer-Ingelheim.
Last updated: Jan 27th, 2015
Stephan Moll, MD writes… The annual meeting of the American Society of Hematology (ASH) took place this month (Dec 6-12th, 2013) in New Orleans. The clinically relevant highlights about thrombosis and anticoagulation are summarized below. Read the rest of this entry »
Stephan Moll writes…
2012 has been a year with significant progress in the field of venous thromboembolism and anticoagulation. The three most noteworthy, clinically relevant developments were probably (a) the publication of the new ACCP (American College of Chest Physician) guidelines on antithrombotic therapy in February 2012; (b) The FDA-approval of rivaroxaban (Xarelto) in November 2012 for the acute treatment of venous thromboembolism (VTE) and long-term secondary prevention; and (c) The FDA-approval of apixaban (Eliquis) in December 2012 for atrial fibrillation and the prevention of arterial thromboembolism. Here I have listed and summarized the 10 top publications of 2012 in the field of venous thromboembolism and anticoaguation as I see them – the ones clinically most relevant.
Disclosure: I have consulted for Janssen, Boehringer-Ingelheim and Daiichi.
Last updated: Feb 7th, 2013
The annual meeting of the American Society of Hematology (ASH) took place in San Diego from Dec 10-13, 2011. Abstracts on thrombosis and anticoagulation that I found interesting and clinically relevant are summarized and put into a clinical perspective in this summary document. Only one abstract was, in my assessment, clinical-practice-changing – abstract #543: “Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked VTE. The WARFASA study”. It is the first abstract discussed in the summary document.
Disclosure: I have no conflict of interest relevant to this post.
Last updated: Dec 13th, 2011